Results
|
1.
|
|
|
2.
|
|
|
3.
|
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. MedStar authors:
- Alsaadi, Dana
- Charabaty, Aline
- Jennings, Joseph
Year: 2018
Citation: - Journal for Immunotherapy of Cancer. 6(1):142, 2018 Dec 05.
Institution: - MedStar Washington Hospital Center
Department: - Gastroenterology/Hepatology
Medline publication type:
All authors: - Abu-Sbeih H, Ali FS, Alsaadi D, Charabaty A, Gong Z, Jennings J, Luo W, Richards DM, Wang Y
|
|
4.
|
A case of checkpoint inhibitor-induced celiac disease. MedStar authors:
Year: 2019
Citation: - Journal for Immunotherapy of Cancer. 7(1):203, 2019 08 05.
Institution: - MedStar Washington Hospital Center
Department: - Medicine/Internal Medicine
Medline publication type:
All authors: - Alsaadi D, Atkins MB, Charabaty A, Shah NJ
|
|
5.
|
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. MedStar authors:
Year: 2020
Citation: - Clinical Cancer Research. 26(6):1258-1266, 2020 03 15.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Attia S, Bolejack V, Burgess M, Davis LE, Hu J, Keung EZ, Lazar AJ, Movva S, Okuno S, Parra Cuentas E, Priebat DA, Reed DR, Reinke DK, Reuben A, Riedel RF, Rodrigues-Canales J, Roland CL, Salazar R, Schuetze SM, Tawbi HA, Van Tine BA, Wang WL, Wargo JA
|
|
6.
|
|
|
7.
|
|